PRMT5-MTA-IN-8

Overview

PRMT5-MTA-IN-8 is an orally active PRMT5-MTA complex inhibitor ( IC 50 = 4.4 nM). PRMT5-MTA-IN-8 inhibits the intracellular production of symmetric dimethylarginine (SDMA) as well as the proliferation of MTAP-deficient cells. PRMT5-MTA-IN-8 exerts antitumor efficacy by inhibiting PRMT5 , reducing SDMA levels and inducing tumor cell apoptosis in mouse models of triple-negative breast cancer . PRMT5-MTA-IN-8 can be used in research related to cancers such as triple-negative breast cancer .

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Triple-Negative Breast Cancer | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Signaling Pathways > Histone Methyltransferase | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-181260
• CAS No.: 3105952-57-3
• Molecular Formula: C19H17BrN6O2
• Molecular Weight: 441.28
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source